Literature DB >> 21329390

Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays.

Omar N Akram1, Christina Bursill, Reena Desai, Alison K Heather, Rymantas Kazlauskas, David J Handelsman, Gilles Lambert.   

Abstract

Androgenic steroids marketed online as nutraceuticals are a growing concern in sport doping. The inability of conventional mass spectrometry (MS)-based techniques to detect structurally novel androgens has led to the development of in vitro androgen bioassays to identify such designer androgens by their bioactivity. The objective of this study was to determine the androgenic bioactivity of novel steroidal compounds isolated from nutraceuticals using both yeast and mammalian cell-based androgen bioassays. We developed two new in vitro androgen bioassays by stably transfecting HEK293 and HuH7 cells with the human androgen receptor (hAR) expression plasmid together with a novel reporter gene vector (enhancer/ARE/SEAP). The yeast β-galactosidase androgen bioassay was used for comparison. Our new bioassay featuring the enhancer/ARE/SEAP construct (-S) displayed simpler assay format and higher specificity with lower sensitivity compared with the commonly used mouse mammary tumour virus (MMTV)-luciferase. The relative potencies (RP), defined as [EC(50)] of testosterone/[EC(50)] of steroid, of nutraceutical extracts in the yeast, HEK293-S, and HuH7-S, were 34, 333, and 80,000 for Hemapolin; 208, 250, and 80 for Furazadrol; 0.38, 10, and 106 for Oxyguno; 2.7, 0.28, and 15 for Trena; and 4.5, 0.1, and 0.4 for Formadrol, respectively. The wide discrepancies in rank RP of these compounds was reconciled into a consistent potency ranking when the cells were treated with meclofenamic acid, a nonselective inhibitor of steroid metabolizing enzymes. These findings indicate that steroids extracted from nutraceuticals can be converted in vitro into more or less potent androgens in mammalian but not in yeast cells. We conclude that the putative androgenic bioactivity of a new compound may depend on the bioassay cellular format and that mammalian cell bioassays may have an added benefit in screening for proandrogens but sacrifice specificity for sensitivity in quantitation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21329390     DOI: 10.1021/ac102845y

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  5 in total

Review 1.  Illicit use of androgens and other hormones: recent advances.

Authors:  Gen Kanayama; Harrison G Pope
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-06       Impact factor: 3.243

2.  Clinical significance of 11-oxygenated androgens.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-06       Impact factor: 3.243

3.  Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes.

Authors:  José Vicente Castell; Ramiro Jover; Petar D Petrov; Leonor Fernández-Murga; Isabel Conde; Teresa Martínez-Sena; Carla Guzmán
Journal:  Arch Toxicol       Date:  2020-01-01       Impact factor: 5.153

Review 4.  In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism.

Authors:  Valery M Dembitsky
Journal:  Mar Drugs       Date:  2021-11-22       Impact factor: 5.118

Review 5.  In vitro androgen bioassays as a detection method for designer androgens.

Authors:  Elliot R Cooper; Kristine C Y McGrath; Alison K Heather
Journal:  Sensors (Basel)       Date:  2013-02-06       Impact factor: 3.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.